5th TCR-based Therapies for Solid Tumors Summit

In the midst of Immunocore's pioneering TCR bispecific product entering commercial markets and the $1.6 billion collaboration between Immatics and Moderna, the TCR space is witnessing a period of unprecedented momentum.

Given these recent advancements, there could be no better time for the 5th TCR-based Therapies for Solid Tumors Summit to return in April, gathering 30+ industry experts, it serves as the ultimate forum to network with senior leaders in biopharma and explore these recent milestones in the TCR space.

Download the event guide here: https://ter.li/24rmoe

Take advantage of this exclusive opportunity to come together and explore enhancing TCR strategies against solid tumors through optimized patient selection, accelerated scalability, and novel combination approaches.

Secure your pass here: https://ter.li/xl0b83